Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Rayonier Advanced Materials	American Vanguard	Wallbridge Mining	Nomad Royalty	Zomedica
Symbol	NYSE:RYAM	NYSE:AVD	TSE:WM	TSE:NSR	NYSEAMERICAN:ZOM
Price Information
Current Price	$5.84	$15.08	C$0.40	C$9.45	$0.37
50-Day Moving Average	$6.83	$15.65	C$0.52	C$8.92	$0.00
52-Week Low	$5.31	$14.16	C$0.37	C$7.34	$0.15
52-Week High	$11.30	$22.49	C$0.86	C$12.10	$2.91
MarketRank™
Overall Score	2.2	2.9	1.9	1.7	1.3
Analysis Score	3.5	3.5	3.5	3.2	0.0
Community Score	4.0	4.0	4.5	3.5	4.7
Dividend Score	0.0	1.7	0.0	1.7	0.0
Ownership Score	1.7	3.3	1.7	0.0	1.7
Earnings & Valuation Score	1.9	1.9	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	N/A
Consensus Price Target	$10.00	$23.50	C$1.00	C$12.25	N/A
% Upside from Price Target	71.23% upside	55.84% upside	153.16% upside	29.63% upside	N/A
Trade Information
Market Cap	$372.22 million	$466.49 million	C$322.90 million	C$535.41 million	$365.50 million
Beta	3.54	0.81	N/A	N/A	0.52
Average Volume	486,534	137,525	721,875	25,869	70,273,797
Sales & Book Value
Annual Revenue	$1.74 billion	$458.70 million	N/A	C$27.15 million	N/A
Price / Sales	0.21	1.02	N/A	19.72	N/A
Cashflow	$2.36 per share	$1.34 per share	C$0.07 per share	C$0.42 per share	N/A
Price / Cash	2.47	11.23	6.06	22.37	N/A
Book Value	$12.32 per share	$11.91 per share	C$0.40 per share	C$4.77 per share	$0.28 per share
Price / Book	0.47	1.27	N/A	1.98	N/A
Profitability
Net Income	$560 thousand	$15.24 million	N/A	N/A	$-16.91 million
EPS	$1.53	$0.71	C($0.02)	C$0.22	($0.06)
Trailing P/E Ratio	3.82	21.24	N/A	42.38	N/A
Forward P/E Ratio	N/A	16.94	∞	∞	∞
P/E Growth	2.26	N/A	N/A	N/A	N/A
Net Margins	5.86%	4.01%	N/A	N/A	N/A
Return on Equity (ROE)	-4.65%	5.93%	N/A	N/A	-8.80%
Return on Assets (ROA)	-1.34%	3.02%	N/A	N/A	-8.52%
Dividend
Annual Payout	N/A	$0.08	C$1.86	C$0.16	N/A
Dividend Yield	N/A	0.53%	470.89%	1.68%	N/A
Three-Year Dividend Growth	N/A	-33.33%	N/A	N/A	N/A
Payout Ratio	N/A	11.27%	N/A	71.01%	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	1.18	0.37	0.04	20.25	N/A
Current Ratio	2.58	2.11	4.96	2.28	56.39
Quick Ratio	1.92	1.17	4.96	2.04	56.10
Ownership Information
Institutional Ownership Percentage	72.60%	79.33%	N/A	N/A	13.36%
Insider Ownership Percentage	3.82%	5.70%	N/A	N/A	1.99%
Miscellaneous
Employees	4,000	771	48,250	6	19
Shares Outstanding	63.74 million	30.93 million	817.46 million	56.66 million	979.90 million
Next Earnings Date	2/23/2022 (Estimated)	3/10/2022 (Estimated)	3/18/2022 (Estimated)	2/17/2022 (Estimated)	2/24/2022 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Zomedica Corp (ZOM) Stock Loses -19.05% This Week; Should You Buy? - InvestorsObserver investorsobserver.com - December 6 at 11:42 PM
	Fetch dvm360®: Saturday's featured sessions - DVM 360 dvm360.com - December 4 at 7:07 AM
	Analysts Predict Zomedica Corp. (AMEX:ZOM) To Reach $1.20 In 12 Months marketingsentinel.com - December 3 at 2:11 PM
	Zomedica Stock Looks Tempting Here, But There’s Likely More Downside investorplace.com - December 3 at 7:03 AM
	Weak Fundamental Momentum Pushes Zomedica Corp. (ZOM) Lower marketingsentinel.com - November 30 at 1:37 PM
	Is Zomedica Corp. (AMEX: ZOM) A Good Investment For New Investors Now? stocksregister.com - November 26 at 12:24 PM
	Zomedica Corp. (NYSEAMERICAN:ZOM) Director Johnny D. Powers Acquires 250,000 Shares americanbankingnews.com - November 22 at 11:20 PM
	Should You Sell Zomedica Corp (ZOM) Stock Monday? - InvestorsObserver investorsobserver.com - November 22 at 6:14 PM
	Market cap of Zomedica Corp. [ZOM] reaches 450.80M – now what? dbtnews.com - November 22 at 5:36 PM
	Antibiotics in Aquaculture Market Report \| Valuates Reports With Fengchen Group Co.,Ltd, Bayer AG, Merck KGaA, - openPR openpr.com - November 19 at 6:43 AM
	Why Zomedica Stock Is Sinking This Week - Motley Fool fool.com - November 18 at 5:47 PM
	Feed antibiotics Market To Get Catalyzed With Technological Advancements 2027 \|\| – LSMedia - LSMedia liverpoolstudentmedia.com - November 18 at 12:43 PM
	Zomedica Is Languishing Today, but Keep an Eye on This Risky Play - Investorplace.com investorplace.com - November 18 at 1:20 AM
	Zomedica Is Languishing Today, but Keep an Eye on This Risky Play investorplace.com - November 17 at 5:09 PM
	Feed Antibiotics Market Size, Growth (2021-2028) \| Top Companies – Bayer, Merck, Zomedica, Elanco, Sanofi, Lg Chem, Luitpold Pharmaceuticals, , – Energy Siren - Energy Siren energysiren.co.ke - November 17 at 5:17 AM
	Is Zomedica Corp (ZOM) Stock a Good Value Monday? - InvestorsObserver investorsobserver.com - November 15 at 5:41 PM
	Zomedica (NYSEAMERICAN:ZOM) Shares Gap Down to $0.54 americanbankingnews.com - November 15 at 1:05 PM
	Thinking about buying stock in Creative Realities, Zomedica, Paysafe, Genius Brands, or Canopy Growth Corp? - PRNewswire prnewswire.com - November 15 at 12:41 PM
	ZOMEDICA CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - marketscreener.com marketscreener.com - November 12 at 6:08 PM
	Zomedica posts widening Q3 net loss as SG&A expenses more than doubles - Seeking Alpha seekingalpha.com - November 12 at 6:08 PM
	Zomedica Announces Third Quarter 2021 Financial Results - Yahoo Finance finance.yahoo.com - November 12 at 6:08 PM
	Zomedica Announces Third Quarter 2021 Financial Results finance.yahoo.com - November 12 at 6:08 PM
	MSCI adds ZOM, CLOV, 110 others to US Micro Cap Index, MNKD, SAVA to be deleted - Seeking Alpha seekingalpha.com - November 12 at 3:06 PM
	Feed Antibiotics Market Size and Outlook 2028 \| Top Companies - Bayer, Merck, Zomedica, Elanco, Sanofi, Lg Chem, Luitpold Pharmaceuticals, , - Energy Siren energysiren.co.ke - November 11 at 3:04 PM
	Global Medical Cotton Market 2021 Future Set to Massive Growth with High CAGR value \| Market Players: Medline Industries, Dynarex, Johnson & Johnson, Becton Dickinson, 3M, Cardinal Health, Shield L... - Energy Siren energysiren.co.ke - November 10 at 11:13 PM

Date	Company	Brokerage	Action
11/24/2021	American Vanguard	Roth Capital	Reiterated Rating
11/24/2021	Nomad Royalty	Canaccord Genuity	Lower Price Target
11/24/2021	Nomad Royalty	CIBC	Boost Price Target
11/12/2021	Wallbridge Mining	Eight Capital	Lower Price Target
11/1/2021	Nomad Royalty	Raymond James	Boost Price Target
10/15/2021	Nomad Royalty	CIBC	Reiterated Rating
10/13/2021	Nomad Royalty	Raymond James	Lower Price Target
10/5/2021	Nomad Royalty	Scotiabank	Lower Price Target
8/23/2021	Nomad Royalty	CIBC	Lower Price Target
8/20/2021	Nomad Royalty	Raymond James	Reiterated Rating
8/20/2021	Nomad Royalty	Scotiabank	Boost Price Target
8/5/2021	Rayonier Advanced Materials	Royal Bank of Canada	Upgrade
7/30/2021	Nomad Royalty	Raymond James	Lower Price Target
7/29/2021	Nomad Royalty	CIBC	Reiterated Rating
7/16/2021	Nomad Royalty	Canaccord Genuity	Boost Price Target
6/30/2021	Nomad Royalty	CIBC	Reiterated Rating
6/29/2021	Nomad Royalty	Raymond James	Reiterated Rating
6/29/2021	Nomad Royalty	Canaccord Genuity	Boost Price Target
6/3/2021	Nomad Royalty	Canaccord Genuity	Reiterated Rating
5/18/2021	Nomad Royalty	Raymond James	Boost Price Target
5/14/2021	Nomad Royalty	CIBC	Reiterated Rating
5/12/2021	Nomad Royalty	Raymond James	Reiterated Rating
5/11/2021	Rayonier Advanced Materials	Royal Bank of Canada	Reiterated Rating
5/11/2021	Nomad Royalty	Royal Bank of Canada	Reiterated Rating
5/5/2021	Rayonier Advanced Materials	Royal Bank of Canada	Downgrade
5/4/2021	American Vanguard	Roth Capital	Boost Price Target
5/4/2021	American Vanguard	Loop Capital	Boost Price Target
4/20/2021	Wallbridge Mining	Eight Capital	Lower Price Target
4/15/2021	Nomad Royalty	Raymond James	Reiterated Rating
4/14/2021	Nomad Royalty	CIBC	Initiated Coverage
4/6/2021	Nomad Royalty	Raymond James	Lower Price Target
11/16/2020	Zomedica	HC Wainwright	Lower Price Target
10/20/2020	Rayonier Advanced Materials	Royal Bank of Canada	Upgrade
10/14/2020	Wallbridge Mining	Eight Capital	Boost Price Target
8/20/2020	Rayonier Advanced Materials	Royal Bank of Canada	Reiterated Rating
8/12/2020	Zomedica	HC Wainwright	Reiterated Rating
7/13/2020	Rayonier Advanced Materials	Royal Bank of Canada	Reiterated Rating
6/19/2020	Rayonier Advanced Materials	Bank of America	Upgrade
6/17/2020	Zomedica	HC Wainwright	Reiterated Rating
6/5/2020	Rayonier Advanced Materials	Royal Bank of Canada	Downgrade
5/21/2020	Wallbridge Mining	Eight Capital	Boost Price Target
5/7/2020	Rayonier Advanced Materials	Royal Bank of Canada	Reiterated Rating
4/21/2020	Wallbridge Mining	Eight Capital	Boost Price Target
2/27/2020	Rayonier Advanced Materials	DA Davidson	Reiterated Rating
10/22/2019	American Vanguard	Loop Capital	Lower Price Target
10/16/2019	Rayonier Advanced Materials	Berenberg Bank	Downgrade
8/9/2019	Rayonier Advanced Materials	Royal Bank of Canada	Set Price Target
8/8/2019	Rayonier Advanced Materials	Sidoti	Downgrade
8/8/2019	Rayonier Advanced Materials	Bank of America	Downgrade
6/5/2019	Zomedica	HC Wainwright	Reiterated Rating
5/10/2019	Rayonier Advanced Materials	DA Davidson	Lower Price Target

(Data available from 12/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources